David Sheridan
David Sheridan
Associate Professor (Senior Lecturer) in Hepatology & Honorary Consultant Hepatologist
Verified email at plymouth.ac.uk - Homepage
Title
Cited by
Cited by
Year
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
V Suppiah, M Moldovan, G Ahlenstiel, T Berg, M Weltman, ML Abate, ...
Nature genetics 41 (10), 1100, 2009
21782009
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study
V Suppiah, S Gaudieri, NJ Armstrong, KS O'Connor, T Berg, M Weltman, ...
PLoS medicine 8 (9), 2011
1182011
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease
M Eslam, AM Hashem, R Leung, M Romero-Gomez, T Berg, GJ Dore, ...
Nature communications 6 (1), 1-10, 2015
1132015
Lipids and HCV
MF Bassendine, DA Sheridan, SH Bridge, DJ Felmlee, RDG Neely
Seminars in immunopathology 35 (1), 87-100, 2013
922013
Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease
PJ Eddowes, M Sasso, M Allison, E Tsochatzis, QM Anstee, D Sheridan, ...
Gastroenterology 156 (6), 1717-1730, 2019
702019
Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles
DJ Felmlee, DA Sheridan, SH Bridge, SU Nielsen, RW Milne, CJ Packard, ...
Gastroenterology 139 (5), 1774-1783. e6, 2010
682010
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised …
D Jones, PF Boudes, MG Swain, CL Bowlus, MR Galambos, BR Bacon, ...
The lancet Gastroenterology & hepatology 2 (10), 716-726, 2017
622017
HCV and the hepatic lipid pathway as a potential treatment target
MF Bassendine, DA Sheridan, DJ Felmlee, SH Bridge, GL Toms, ...
Journal of hepatology 55 (6), 1428-1440, 2011
622011
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes
M Eslam, A Mangia, T Berg, HLY Chan, WL Irving, GJ Dore, ML Abate, ...
Hepatology 64 (1), 34-46, 2016
562016
IFN-λ3, not IFN-λ4, likely mediates IFNL3IFNL4 haplotype–dependent hepatic inflammation and fibrosis
M Eslam, D McLeod, KS Kelaeng, A Mangia, T Berg, K Thabet, WL Irving, ...
Nature Genetics 49 (5), 795, 2017
522017
FibroGENE: A gene-based model for staging liver fibrosis
M Eslam, AM Hashem, M Romero-Gomez, T Berg, GJ Dore, A Mangia, ...
Journal of hepatology 64 (2), 390-398, 2016
472016
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
452019
Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH: 938
Z Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
American Journal of Gastroenterology 114 (2019 ACG Annual Meeting Abstracts …, 2019
452019
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
K Thabet, A Asimakopoulos, M Shojaei, M Romero-Gomez, A Mangia, ...
Nature communications 7 (1), 1-8, 2016
452016
Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha …
DA Sheridan, DA Price, ML Schmid, GL Toms, P Donaldson, D Neely, ...
Alimentary pharmacology & therapeutics 29 (12), 1282-1290, 2009
442009
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection
M Eslam, R Leung, M Romero-Gomez, A Mangia, WL Irving, D Sheridan, ...
Journal of hepatology 61 (2), 235-241, 2014
422014
Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity
DA Sheridan, SH Bridge, DJ Felmlee, MME Crossey, HC Thomas, ...
Journal of hepatology 57 (1), 32-38, 2012
392012
Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)
DA Sheridan, RDG Neely, MF Bassendine
Clinics and research in hepatology and gastroenterology 37 (1), 10-16, 2013
362013
PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism
SH Bridge, DA Sheridan, DJ Felmlee, MME Crossey, FI Fenwick, ...
Journal of hepatology 62 (4), 763-770, 2015
302015
Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection
SH Bridge, DA Sheridan, DJ Felmlee, SU Nielsen, HC Thomas, ...
Gut 60 (5), 680-687, 2011
232011
The system can't perform the operation now. Try again later.
Articles 1–20